Towards a national registry for Alzheimer's disease and related dementias: rationale, design, and initial observations of the ABOARD cohort.

IF 7.6 1区 医学 Q1 CLINICAL NEUROLOGY
Casper de Boer, Hanneke F M Rhodius-Meester, Sophie M van der Landen, Jurgen Claassen, Romy de Haan, Janne M Papma, Harro Seelaar, Marleen Kloppenburg-Lagendijk, Barbara van Munster, Marjolein de Vugt, Derk Arts, Marco Blom, Tanja J de Rijke, Miriam Beusink, Robbert Huijsman, Evert-Ben van Veen, Argonde van Harten, Jort Vijverberg, Marissa Zwan, Henk-Jan Mutsaerts, Sven J van der Lee, Wiesje M van der Flier
{"title":"Towards a national registry for Alzheimer's disease and related dementias: rationale, design, and initial observations of the ABOARD cohort.","authors":"Casper de Boer, Hanneke F M Rhodius-Meester, Sophie M van der Landen, Jurgen Claassen, Romy de Haan, Janne M Papma, Harro Seelaar, Marleen Kloppenburg-Lagendijk, Barbara van Munster, Marjolein de Vugt, Derk Arts, Marco Blom, Tanja J de Rijke, Miriam Beusink, Robbert Huijsman, Evert-Ben van Veen, Argonde van Harten, Jort Vijverberg, Marissa Zwan, Henk-Jan Mutsaerts, Sven J van der Lee, Wiesje M van der Flier","doi":"10.1186/s13195-025-01725-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Alzheimer's disease and related dementias (ADRD) take 20 to 30 years to develop, yet setting up studies or registries that take into account the entire disease trajectory is difficult and time consuming. Moreover, prediction models are often based on selected research populations and their outcomes may not be most relevant to patients' daily lives. To address these gaps we set up the ABOARD Cohort, a national data collection infrastructure to (i) study the disease trajectory using patient reported outcome measures (PROMs) and medical data, (ii) link to available data sources, and (iii) serve as central platform to facilitate research, roll out healthcare innovations, and accommodate nationwide disease registration. Here, we describe the design of the project and characteristics of the first 10,275 participants.</p><p><strong>Method: </strong>The ABOARD Cohort is an ongoing, participant-centered data-collection, taking PROMs and a minimal case report form (CRF) with relevant medical data as starting point, supplemented with linkage to existing data sources. Eligible participants with or at-risk of ADRD a and their study partners are recruited directly-to-participant, i.e. without the need for a doctor to sign informed consent. Informed consent and annual collection of PROMs are fully online. Relevant stakeholders are involved in decisions on project development through a participants panel and on data usage through a data access committee.</p><p><strong>Results: </strong>The ABOARD Cohort has been fully operational since January 2023. As of October 2024, 10,275 participants (mean age 66.1 (9.2) years, 70% female) and 1,383 study partners signed up, and received an invitation to fill in online questionnaires and complete a digital cognitive test. Over 90% of participants gave consent to link their data to existing data sources. Participants who had consulted a doctor for memory problems (N = 1,128), reported worse outcomes on PROMs assessing mental health and cognition, quality of life and lifestyle, compared to those who had not.</p><p><strong>Conclusion: </strong>The ABOARD Cohort has been set up as a national infrastructure to study ADRD disease trajectories, linking data-sources, with the participant at the steering wheel. This infrastructure has the potential to serve as a registry to advance research and roll out healthcare innovations on a national level.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"17 1","pages":"123"},"PeriodicalIF":7.6000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12125861/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's Research & Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13195-025-01725-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Alzheimer's disease and related dementias (ADRD) take 20 to 30 years to develop, yet setting up studies or registries that take into account the entire disease trajectory is difficult and time consuming. Moreover, prediction models are often based on selected research populations and their outcomes may not be most relevant to patients' daily lives. To address these gaps we set up the ABOARD Cohort, a national data collection infrastructure to (i) study the disease trajectory using patient reported outcome measures (PROMs) and medical data, (ii) link to available data sources, and (iii) serve as central platform to facilitate research, roll out healthcare innovations, and accommodate nationwide disease registration. Here, we describe the design of the project and characteristics of the first 10,275 participants.

Method: The ABOARD Cohort is an ongoing, participant-centered data-collection, taking PROMs and a minimal case report form (CRF) with relevant medical data as starting point, supplemented with linkage to existing data sources. Eligible participants with or at-risk of ADRD a and their study partners are recruited directly-to-participant, i.e. without the need for a doctor to sign informed consent. Informed consent and annual collection of PROMs are fully online. Relevant stakeholders are involved in decisions on project development through a participants panel and on data usage through a data access committee.

Results: The ABOARD Cohort has been fully operational since January 2023. As of October 2024, 10,275 participants (mean age 66.1 (9.2) years, 70% female) and 1,383 study partners signed up, and received an invitation to fill in online questionnaires and complete a digital cognitive test. Over 90% of participants gave consent to link their data to existing data sources. Participants who had consulted a doctor for memory problems (N = 1,128), reported worse outcomes on PROMs assessing mental health and cognition, quality of life and lifestyle, compared to those who had not.

Conclusion: The ABOARD Cohort has been set up as a national infrastructure to study ADRD disease trajectories, linking data-sources, with the participant at the steering wheel. This infrastructure has the potential to serve as a registry to advance research and roll out healthcare innovations on a national level.

Abstract Image

Abstract Image

Abstract Image

面向阿尔茨海默病和相关痴呆的国家登记:ABOARD队列的基本原理、设计和初步观察
背景:阿尔茨海默病和相关痴呆(ADRD)需要20至30年的发展,但建立考虑整个疾病轨迹的研究或登记是困难和耗时的。此外,预测模型通常基于选定的研究人群,其结果可能与患者的日常生活不太相关。为了解决这些差距,我们建立了ABOARD队列,这是一个国家数据收集基础设施,用于(i)使用患者报告的结果测量(PROMs)和医疗数据研究疾病轨迹,(ii)链接到可用的数据源,以及(iii)作为促进研究的中心平台,推出医疗保健创新,并适应全国疾病登记。在这里,我们描述了项目的设计和第一批10275名参与者的特征。方法:ABOARD队列是一项持续的、以参与者为中心的数据收集,以prom和包含相关医疗数据的最小病例报告表(CRF)为起点,辅以与现有数据源的链接。患有或有ADRD a风险的符合条件的参与者及其研究伙伴直接被招募为参与者,即不需要医生签署知情同意书。知情同意和每年收集prom完全在网上进行。相关利益相关者通过参与者小组参与项目开发决策,并通过数据访问委员会参与数据使用决策。结果:自2023年1月起,ABOARD队列已全面投入使用。截至2024年10月,10,275名参与者(平均年龄66.1(9.2)岁,70%为女性)和1,383名研究伙伴签署了协议,并收到了填写在线问卷和完成数字认知测试的邀请。超过90%的参与者同意将他们的数据链接到现有的数据源。曾因记忆问题咨询过医生的参与者(N = 1128)在评估心理健康、认知、生活质量和生活方式的PROMs测试中报告的结果比没有咨询过医生的人更差。结论:ABOARD队列已建立为研究ADRD疾病轨迹的国家基础设施,将数据源与方向盘上的参与者联系起来。这一基础设施具有作为登记处的潜力,可以在国家层面上推进研究和推出医疗保健创新。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Alzheimer's Research & Therapy
Alzheimer's Research & Therapy 医学-神经病学
CiteScore
13.10
自引率
3.30%
发文量
172
审稿时长
>12 weeks
期刊介绍: Alzheimer's Research & Therapy is an international peer-reviewed journal that focuses on translational research into Alzheimer's disease and other neurodegenerative diseases. It publishes open-access basic research, clinical trials, drug discovery and development studies, and epidemiologic studies. The journal also includes reviews, viewpoints, commentaries, debates, and reports. All articles published in Alzheimer's Research & Therapy are included in several reputable databases such as CAS, Current contents, DOAJ, Embase, Journal Citation Reports/Science Edition, MEDLINE, PubMed, PubMed Central, Science Citation Index Expanded (Web of Science) and Scopus.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信